Numerical abnormalities of chromosomes 7, 18, and X in precancerous breast disease defined by fluorescent in situ hybridization

Breast Journal

Volumn 4, Issue 4, 1998, Pages 252-257

  Illei, Peter B ^a   Feiner, Helen D ^a   Symmans, William F ^a   Mitnick, Julie S ^a   Roses, Daniel F ^a   Perle, Mary Ann ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aneusomy; Atypical ductal hyperplasia; Ductal carcinoma in situ; Ductal hyperplasia; Fluorescent in situ hybridization; Interphase cytogenetics

Indexed keywords

ARTICLE; BREAST CANCER; CANCER INVASION; CELL DEATH; CELL PROLIFERATION; CHROMOSOME 18; CHROMOSOME 7; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERPHASE; INTRADUCTAL CARCINOMA; NUMERICAL CHROMOSOME ABERRATION; TISSUE SECTION;

EID: 0031869188     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.1998.440252.x     Document Type: Article

References (31)

1. Page DL, Anderson TJ, Rogers LW. Epithelial hyperplasia. In: Page DL, Anderson TJ, eds. Diagnostic Histopathology of the Breast. New York: Churchill Livingstone, 1987: 120-56.
2. Tavassoli FA. Intraductal hyperplasias, ordinary and atypical. In: Tavassoli FA, ed. Pathology of the Breast. Norwalk, CT: Appleton & Lange, 1992:155-90.
3. Rosen PP, Oberman HA. Intraepithelial (preinvasive and in situ) carcinoma. In: Atlas of Tumor Pathology: Tumors of the Mammary Gland. Washington, DC: AFIP, 1993:135-42.
4. Jensen RA, Dupont WD, Page DL. Diagnostic criteria and cancer risk of proliferative breast lesions. J Cell Biochem 1993;17G:59-64.
5. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long term follow-up study. Cancer 1985;55:2698-708.
6. Page DL. Cancer risk assessment in benign breast biopsies. Hum Pathol 1986;17:871-74.
7. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Eng J Med 1985; 312:146-51.
8. Palli D, Roselli del Turco M, Simonici R, Bianchi S. Benign breast disease and breast cancer: A case control study in a cohort in Italy. Cancer 1991;47:703-6.
9. London SJ, Conolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and risk of breast cancer. JAMA 1992;267:941-44.
10. Dupont WD, Pari FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71:1258-65.
11. Fabian CJ, Zalles C, Kamel Z, et al. Biomarkers and cytologic abnormalities in women at high and low risk for breast cancer. J Cell Biochem 1993;17G:153-60.
12. Erikkson ET, Schimmelpenning H, Aspenblad U, Zetterberg A, Auer G. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. Hum Pathol 1994;25:1228-33.
13. Allred DC, O'Connell P, Fuqua SAQ. Biomarkers in early breast neoplasia. J Cell Biochem 1993;17G:125-31.
14. Khan SA, Rogers MAM, Obando JA, Tamsen A. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Can Res 1994;54:993-97.
15. Younes M, Lebovitz RM, Bommer KE, et al. p53 accumulation in benign breast biopsy specimens. Hum Pathol 1995;26:155-58.
16. Moreno A, Lloveras B, Figueras A, et al. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. Hum Pathol 1997;10:1088-92.
17. Milikan R, Hulka B, Thor A, et al. p53 mutation in benign breast tissue. J Clin Oncol 1995;13:2293-300.
18. Schmitt FC, Leal C, Lopes C. p53 protein expression and nuclear DNA content in breast intraductal proliferations. J Pathol 1995;176:233-41.
19. O'Connell P, Pekkel V, Fuqua SAW, Osborne CK, Allred DC. Molecular genetic studies of early breast cancer evolution by LOH. Breast Cancer Res Treat 1994;32:5-12.
20. Smith HS, Lu Y, Deng G, et al. Molecular aspects of early stages of breast cancer progression. J Cell Biochem 1993; 17G:144-52.
21. Pandis N, Jing Y, Gorunova L, et al. Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups. Gen Chrom Cancer 1995;12:173-85.
22. Sneige N, Sahin A, Dinh M, El-Nagger A. Interphase cytogenetics in mammographically detected breast lesions. Hum Pathol 1996;27:330-35.
23. Micale MA, Visscher DW, Gulino SE, Wolman SR. Chromosomal aneuploidy in proliferative breast disease. Hum Pathol 1994;25:29-35.
24. Cajulis RS, Frias-Hidvegi D. Detection of numerical chromosomal abnormalities in malignant cells in fine needle aspirates by fluorescent in situ hybridization of interphase cell nuclei with chromosome-specific probes. Acta Cytol 1993;37:391-96.
25. Hopman AHN, Ramaekers FCS, Raap AK, Beck JLM, Devilee P, van der Ploeg M. In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochem 1988;89:307-16.
26. Herrington CS, Cooper K, McGee JO. Interphase cytogenetics: analysis of numerical chromosome aberrations in isolated cells. J Pathol 1995;175:283-95.
27. Meisner LF, Han K, Lee W, Harris CP. Assessing aneuploidy in normal tissues with FISH: pitfalls and insights. Cancer Genet Cytogenet 1994;72:78-80.
28. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 1996;148:313-19.
29. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol 1991;15:209-21.
30. Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995;1:1257-60.
31. Steeg PS, Clare SE, Lawrence JA, Zhou Q. Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. Am J Pathol 1996;149:733-38.